- cafead May 08, 2024 at 11:42: AM
via Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval. The drug is a type of BTK inhibitor that combats disorders found in B lymphocytes, also known as B cells. BTK inhibitors have shown effectiveness as a treatment for such diseases as non-Hodgkin lymphomas.
article source
article source